EurekaMag.com logo
+ Site Statistics
References:
53,869,633
Abstracts:
29,686,251
+ Search Articles
+ Subscribe to Site Feeds
EurekaMag Most Shared ContentMost Shared
EurekaMag PDF Full Text ContentPDF Full Text
+ PDF Full Text
Request PDF Full TextRequest PDF Full Text
+ Follow Us
Follow on FacebookFollow on Facebook
Follow on TwitterFollow on Twitter
Follow on LinkedInFollow on LinkedIn

+ Translate

Randomized multicenter phase II trial of subcutaneous recombinant human interleukin-12 versus interferon-alpha 2a for patients with advanced renal cell carcinoma



Randomized multicenter phase II trial of subcutaneous recombinant human interleukin-12 versus interferon-alpha 2a for patients with advanced renal cell carcinoma



Journal of Interferon & Cytokine Research 21(4): 257-263



Recombinant human interleukin-12 (rHuIL-12) is a pleiotropic cytokine with anticancer activity against renal cell carcinoma (RCC) in preclinical models and in a phase I trial. A randomized phase II study of rHuIL-12 compared with interferon-alpha (IFN-alpha) evaluated clinical response for patients with previously untreated, advanced RCC. Patients were randomly assigned 2:1 to receive either rHuIL-12 or IFN-alpha2a. rHuIL-12 was administered by subcutaneous (s.c.) injection on days 1, 8, and 15 of each 28-day cycle. The dose of IL-12 was escalated during cycle 1 to a maintenance dose of 1.25 microg/kg. IFN was administered at 9 million units by s.c. injection three times per week. Serum concentrations of IL-12, IFN-gamma, IL-10, and neopterin were obtained in 10 patients treated with rHuIL-12 after the first full dose of 1.25 microg/kg given on day 15 (dose 3) of cycle 1 and again after multiple doses on day 15 (dose 6) of cycle 2. Thirty patients were treated with rHuIL-12, and 16 patients were treated with IFN-alpha. Two (7%) of 30 patients treated with rHuIL-12 achieved a partial response, and the trial was closed to accrual based on the low response proportion. IL-12 was absorbed rapidly after s.c. drug administration, with the peak serum concentration appearing at approximately 12 h in both cycles. Serum IL-12 concentrations remained stable on multiple dosing. Levels of IFN-gamma, IL-10, and neopterin increased with rHuIL-12 and were maintained in cycle 2. rHuIL-12 is a novel cytokine with unique pharmacologic and pharmacodynamic features under study for the treatment of malignancy and other medical conditions. The low response proportion associated with rHuIL-12 single-agent therapy against metastatic RCC was disappointing, given the preclinical data. Further study of rHuIL-12 for other medical conditions is underway. For RCC, the study of new cytokines is of the highest priority.

(PDF emailed within 0-6 h: $19.90)

Accession: 047168836

Download citation: RISBibTeXText

PMID: 11359657

DOI: 10.1089/107999001750169934



Related references

Subcutaneous recombinant interleukin-2 and alpha-interferon in patients with advanced renal cell carcinoma: results of a multicenter Phase II Study. Cancer BioTherapy 8(4): 289-300, 1993

Subcutaneous interleukin-2 and interferon alpha in the treatment of patients with metastatic renal cell carcinoma-Less efficacy compared with intravenous interleukin-2 and interferon alpha. Results of a multicenter Phase II trial from the Groupe Français d'Immunothérapie. Cancer 95(11): 2324-2330, 2002

Subcutaneous interleukin-2 and interferon alpha in the treatment of patients with metastatic renal cell carcinoma: Less efficacy compared with intravenous interleukin-2 and interferon alpha: Results of a multicenter phase II trial from the Groupe Francais d'lmmunotherapie. Cancer 95(11): 2324-2330, December 1, 2002

Randomized phase III trial of high-dose interleukin-2 versus subcutaneous interleukin-2 and interferon in patients with metastatic renal cell carcinoma. Journal of Clinical Oncology 23(1): 133-141, 2004

Phase I trial of subcutaneous recombinant human interleukin-12 in patients with advanced renal cell carcinoma. Clinical Cancer Research 4(5): 1183-1191, 1998

A comparison of 2 modes of administration of recombinant interleukin-2: continuous intravenous infusion alone versus subcutaneous administration plus interferon alpha in patients with advanced renal cell carcinoma. Cancer BioTherapy 8(2): 123-136, 1993

Multicenter phase III randomized trial of polychemotherapy versus the same chemotherapy plus subcutaneous interleukin-2 and interferon-alpha-2b in metastatic melanoma. EJC Supplements 1(5): S252, September, 2003

Treatment of patients with metastatic renal cell carcinoma with subcutaneous recombinant interferon-alpha 2b and continuous infusion of recombinant interleukin-2: A phase II study. Onkologie 17(3): 254-260, 1994

Subcutaneous interleukin-2 plus alpha-interferon in out-patients with renal metastatic cell carcinoma Results of French multicenter SCAPP III Trial. European Urology 39(Suppl 5): 122, March, 2001

Cisplatin, dacarbazine with or without subcutaneous interleukin-2, and interferon alpha-2b in advanced melanoma outpatients: results from an Italian multicenter phase III randomized clinical trial. Journal of Clinical Oncology 20(6): 1600-1607, 2002

A combination of subcutaneous recombinant interleukin-2 and recombinant interferon-alpha in the treatment of advanced renal cell carcinoma or melanoma. European Journal of Cancer 30a(4): 530-532, 1994

Sequential treatment of patients with advanced renal cell carcinoma with autologous tumor vaccine and subcutaneous administration of recombinant interleukin 2 and interferon alpha 2b. World Journal of Urology 9(4): 223-227, 1991

Multicenter phase II trial of interleukin-2, interferon-alpha, and 13-cis-retinoic acid in patients with metastatic renal-cell carcinoma. Journal of Clinical Oncology 16(5): 1820-1825, 1998

Eortc randomized phase ii study of recombinant interferon alpha and recombinant interferon alpha and gamma in advanced renal cell carcinoma. Journal of Urology 145(4 SUPPL): 272A, 1991

A phase II trial of intravenous gemcitabine and 5-fluorouracil with subcutaneous interleukin-2 and interferon-alpha in patients with metastatic renal cell carcinoma. Cancer 94(10): 2602-2609, 2002